TIDMAGL
Angle PLC
17 October 2017
For immediate release 17 October 2017
ANGLE plc ("the Company")
SEVENTH PEER REVIEWED PUBLICATION ON ANGLE'S PARSORTIX(TM)
SYSTEM
Parsortix(TM) system outperforms other approaches to harvest
circulating tumour cells from the blood of clear cell renal cell
carcinoma patients
The Parsortix(TM) system demonstrated the highest recovery rate
and the highest purity of all evaluated systems
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, today announces that its Parsortix(TM) system is the
subject of a peer-reviewed publication in the journal Oncotarget
detailing work undertaken by ANGLE's customer, University Hospital
Muenster, Germany (Muenster).
Muenster undertook a detailed evaluation of performance of four
different types of systems in their ability to harvest circulating
tumour cells (CTCs) for clear cell renal cell carcinoma (kidney
cancer) patients. The approaches evaluated were (i) antibody-based
capture (EpCAM), (ii) density-based separation and CD45 negative
depletion (removal of white blood cells), (iii) negative enrichment
(removal of white blood cells) and density based centrifugation,
and (iv) the Parsortix(TM) system.
The Parsortix(TM) system out-performed all the other systems on
all the measures investigated and was recommended by the
investigators as the system to use in patients with such renal cell
carcinomas. In particular, the Parsortix(TM) system had both the
highest cell recovery and the highest purity of all the approaches
studied.
The publication is available at
https://angleplc.com/library/publications/
Globally, the incidence of renal cell carcinoma varies widely
from region to region, with the highest rates observed in the Czech
Republic and North America. In the United States, there are
approximately 64,000 new cases and almost 14,000 deaths from renal
cell carcinoma each year. In the European Union, there were
approximately 84,000 cases of renal cell carcinoma and 35,000
deaths due to kidney cancer in 2012.
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"This published study further demonstrates that the
Parsortix(TM) system outperforms others for harvesting circulating
tumour cells from the blood of cancer patients in the fast emerging
liquid biopsy market. ANGLE's strategy of promoting research use
sales to drive widespread adoption of its CTC harvesting system has
now delivered a seventh positive peer-reviewed publication on the
utility of the Parsortix(TM) system, this time in the renal cancer
setting."
Dr Christof Bernemann, Laboratory Head, Clinic for Urology,
University Hospital Muenster, Muenster, Germany, commented:
"The number of studies reporting circulating tumour cell
detection in clear cell renal cell carcinoma patients is small,
reflecting the poor performance of the traditional antibody-based
systems in isolating CTCs in this cancer type. We believe,
therefore, that the outperformance of the Parsortix(TM) system we
have demonstrated should boost research into this cancer,
potentially enabling personalised cancer treatment in the
future."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. Parsortix has a CE Mark for Europe and
FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGGRWUUPMGQQ
(END) Dow Jones Newswires
October 17, 2017 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024